Hair loss can be traumatic and, unfortunately, extremely common. But a New Jersey doctor says he has a new treatment.

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Keranique's Hair Regrowth Treatment is getting rave reviews from Amazon shoppers who swear it helped fill in bald patches ...

Struggling with hair loss? Whether it's due to menopause, postpartum changes, or stress, the right supplements can make a ...

Many people may struggle with hair loss and thinning, and the causes are wide ranging. A dermatologist who specialises in ...

Common Hair Loss and Prostate Drug May Also Cut Heart Disease Risk in Men and Mice Feb. 20, 2024 — The drug finasteride, also known as Propecia or Proscar, treats male pattern baldness and ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Showcase your company news with guaranteed exposure both in print and online 25 years ago, Denver's economy thrived on IT, real estate & oil. DBJ will kick… Be Inspired! Meet Your Mentor! Make ...